Based on the Quest Diagnostics Incorporated stock forecast from 13 analysts, the average analyst target price for Quest Diagnostics Incorporated is USD 173.00 over the next 12 months. Quest Diagnostics Incorporated’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Quest Diagnostics Incorporated is Slightly Bullish , which is based on 7 positive signals and 4 negative signals. At the last closing, Quest Diagnostics Incorporated’s stock price was USD 172.24. Quest Diagnostics Incorporated’s stock price has changed by +2.06% over the past week, +13.43% over the past month and +35.54% over the last year.
No recent analyst target price found for Quest Diagnostics Incorporated
No recent average analyst rating found for Quest Diagnostics Incorporated
Company Overview Quest Diagnostics Incorporated
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey. Read Less
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other d...Read More
Frequently Asked Questions About Quest Diagnostics Incorporated (DGX) Stock
Based on ratings from 13 analysts Quest Diagnostics Incorporated's stock is Buy . Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 9 buy, sell and 11 hold ratings.
DGX stock's dividend yield is 1.90%.
Our analysis grades DGX stock's dividend yield at D+. This means that DGX stock's dividend yield is above 67% of the stocks in the Diagnostics & Research sector in the NYE exchange.
Based on this DGX may be a average dividend stock for its sector.
Based on targets from 13 analysts, the average taret price for DGX is USD 173.00 over the next 12 months. The maximum analyst target price is USD 190 while the minimum anlayst target price is USD 145.
DGX stock's Price/Earning ratio is 21.92.
Our analysis grades DGX stock's Price / Earning ratio at B+. This means that DGX stock's Price/Earning ratio is above 12% of the stocks in the Diagnostics & Research sector in the NYE exchange.
Based on this DGX may be undervalued for its sector.
The last closing price of DGX's stock was USD 172.24.
The most recent market capitalization for DGX is USD 18.67B.
Based on targets from 13 analysts, the average taret price for DGX is projected at USD 173.00 over the next 12 months.
This means that DGX's stock price may go up by +0.44% over the next 12 months.
We can't find any ETFs which contains Quest Diagnostics Incorporated's stock.
As per our most recent records Quest Diagnostics Incorporated has 55,000 Employees.
Quest Diagnostics Incorporated's registered address is 500 Plaza Drive, Secaucus, NJ, United States, 07094.
You can get more information about it from Quest Diagnostics Incorporated's website at https://www.questdiagnostics.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior total returns
The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low Dividend Growth
This stock has shown below median dividend growth in the previous 5 years compared to its sector.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Quest Diagnostics Incorporated (DGX) Stock
Based on ratings from 13 analysts Quest Diagnostics Incorporated's stock is Buy . Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 9 buy, sell and 11 hold ratings.
DGX stock's dividend yield is 1.90%.
Our analysis grades DGX stock's dividend yield at D+. This means that DGX stock's dividend yield is above 67% of the stocks in the Diagnostics & Research sector in the NYE exchange.
Based on this DGX may be a average dividend stock for its sector.
Based on targets from 13 analysts, the average taret price for DGX is USD 173.00 over the next 12 months. The maximum analyst target price is USD 190 while the minimum anlayst target price is USD 145.
DGX stock's Price/Earning ratio is 21.92.
Our analysis grades DGX stock's Price / Earning ratio at B+. This means that DGX stock's Price/Earning ratio is above 12% of the stocks in the Diagnostics & Research sector in the NYE exchange.
Based on this DGX may be undervalued for its sector.
The last closing price of DGX's stock was USD 172.24.
The most recent market capitalization for DGX is USD 18.67B.
Based on targets from 13 analysts, the average taret price for DGX is projected at USD 173.00 over the next 12 months.
This means that DGX's stock price may go up by +0.44% over the next 12 months.
We can't find any ETFs which contains Quest Diagnostics Incorporated's stock.
As per our most recent records Quest Diagnostics Incorporated has 55,000 Employees.
Quest Diagnostics Incorporated's registered address is 500 Plaza Drive, Secaucus, NJ, United States, 07094.
You can get more information about it from Quest Diagnostics Incorporated's website at https://www.questdiagnostics.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for DGX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
